Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan

Journal of Occupational Health

Volumn 48, Issue 6, 2006, Pages 517-522

  Yoshida, Jin ^a   Kosaka, Hiroshi ^a   Tomioka, Kimiko ^a   Kumagai, Shinji ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Antineoplastic drug; Genotoxicity; Lymphocyte DNA damage; Nurse; Work environment contamination

Indexed keywords

ACLARUBICIN; AMRUBICIN; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DNA; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PIRARUBICIN; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMET ASSAY; CONTAMINATION; CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DRUG CONTAMINATION; DRUG EXPOSURE; FEMALE; GENOTOXICITY; HUMAN; JAPAN; LYMPHOCYTE; NURSE; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; WARD; WORK ENVIRONMENT;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DNA DAMAGE; FEMALE; HUMANS; JAPAN; LYMPHOCYTES; MIDDLE AGED; MUTAGENICITY TESTS; NURSING STAFF, HOSPITAL; OCCUPATIONAL EXPOSURE;

EID: 33846034002     PISSN: 13419145     EISSN: 13489585     Source Type: Journal    
DOI: 10.1539/joh.48.517     Document Type: Article

References (25)

1. Black DJ and Livingston RB: Antineoplastic drugs in 1990: a review (Part 1). Drugs 39, 489-501 (1990)
2. Black DJ and Livingston RB: Antineoplastic drugs in 1990: a review (Part 2). Drugs 39, 652-673 (1990)
3. Morimoto S, Horisaka K, Kariya K. Pharmacology categorized by disorder. Tokyo: Hirokawa Publishing Co, 1996: 685-712.
4. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 26: Some Antineoplastic and Immunosuppressive Agents. Lyon: IARC, 1981.
5. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 76: Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. Lyon: IARC, 2000.
6. Sorsa M, Hemminki K and Vainio H: Occupational exposure to anticancer drug - potential and real hazards. Mutat Res 154, 135-149 (1985)
7. Falck K, Grohn P, Sorsa M, Vainio H, Heinonen E and Holsti LR: Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1, 1250-1251 (1979)
8. Thiringer G, Granung G, Holmen A, Hogstedt B, Jarvholm B, Jonsson D, Persson L, Wahlstrom J and Westin J: Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 17, 133-138 (1991)
9. Burgaz S, Karahalil B, Canhi Z, Terzioglu F, Ancel G, Anzion RB, Bos RP and Huttner E: Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol 21, 129-135 (2002)
10. Jakab MG, Major J and Tompa A: Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J Toxicol Environ Health A 62, 307-318 (2001)
11. Undeger U, Basaran N, Kars A and Guc D: Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat Res 439, 277-285 (1999)
12. Hessel H, Radon K, Pethran A, Maisch B, Grobmair S, Sautter I and Fruhmann G: The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs - evaluation by the micronucleus assay. Mutat Res 497, 101-109 (2001)
13. DeMeo MP, Merono S, DeBaille AD, Botta A, Laget M, Guiraud H and Dumenil G: Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials. Int Arch Occup Environ Health 66, 363-368 (1995)
14. Krepinsky A, Bryant DW, Davison L, Young B, Heddle J, McCalla DR, Douglas G and Michalko K: Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ Mol Mutagen 15, 83-92 (1990)
15. Kitada M, Morikawa A, Katou H and Nakayama S. The revised version of guideline of handling antineoplastic drugs in medical center - Manual of handling antineoplastic drugs. Tokyo: Jiho Co, 2005.
16. Isii N, Dakeishi M, Sasaki M and Murata K: Safety awareness of anticancer drug handling among Japanese nurses. Jpn J Public Health 52, 727-735 (2005)
17. Oda Y, Nakamura S, Oki I, Kato T and Shinagawa H: Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat Res 147, 214-229 (1985)
18. Ostling O and Johanson KJ: Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 30, 291-298 (1984)
19. Maluf SW and Erdtmann B: Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat Res 471, 21-27 (2000)
20. Miller JH. Experiments in Molecular Genetics. NY: Cold Spring Harbor, 1972: 352-355.
21. Bos RP and Sessink PJ: Biomonitoring of occupational exposures to cytostatic anticancer drugs. Rev Environ Health 12, 43-58 (1997)
22. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB and Bos RP: Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 64, 105-112 (1992)
23. Ye XB, Fu H, Zhu JL, Ni WM, Lu YW, Kuang XY, Yang SL and Shu BX: A study on oxidative stress in lead-exposed workers. J Toxicol Environ Health A 57, 161-172 (1999)
24. Zhu CQ, Lam TH, Jiang CQ, Wei BX, Xu QR, Chen YH: Increased lymphocyte DNA strand breaks in rubber workers. Mutat Res 470, 201-209 (2000)
25. Lalic H: Cytogenetic monitoring of medical staff professionally exposed to Gamma and X radiation. Neoplasma 52, 307-313 (2005)